In a publication in the Journal of the National Cancer Institute, made available online on September 6, 2006, the international consortium TRANSBIG reports the validation and the clinical utility of Agendia’s Mammaprint® breast cancer prognosis test (TRANSBIG: European Union 6th framework program Translational Research Breast International Group; www.breastinternationalgroup.org). In this study, 307 breast cancer patients from five different European centers were compared for their risk for metastatic disease either by Agendia’s MammaPrint® test or by conventional clinico-pathological risk assessment as determined by the Adjuvant! ® software. The study found that the MammaPrint® gene signature clearly outperformed the clinico-pathological risk assessment in predicting disease outcome and concludes that the MammaPrint® test adds independent prognostic information to clinico-patholoigcal risk analysis in early breast cancer.

Dr. Laura van ‘t Veer, Chief Operating Officer at Agendia comments: ”The independent validation and demonstration of clinical utility of MammaPrint® by the international TRANSBIG consortium brings this test to level 3 of Evidence Based Medicine for a diagnostic test endorsing its routine clinical use”.

About Agendia
Agendia is a world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a prognostic test - MammaPrint® - that predicts the chance of breast cancer recurrence. Agendia maintains close ties with several academic centers, including The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, to ensure access to the latest developments in cancer research. Apart from the development of new cancer diagnostics, Agendia offers its expertise in finding new predictive gene expression profiles to companies focusing on development of new drugs in the area of oncology.